96,427 Shares of DexCom, Inc. $DXCM Bought by HWG Holdings LP

Key Points

• HWG Holdings LP acquired 96,427 DexCom shares worth approximately $8.3 million in the third quarter, making DXCM about 1.9% of its portfolio. Hedge funds and other institutional investors collectively own 97.75% of the company.
• Analysts maintain a positive outlook, with a consensus “Buy” rating and a $91.96 price target; several firms recently raised their targets, including RBC to $105.
• DexCom reported quarterly earnings of $0.70 per share, exceeding estimates, while revenue rose 13.1% year over year to $1.31 billion. Meanwhile, insiders sold 49,313 shares worth about $3.95 million over the past 90 days under pre-arranged trading plans.

HWG Holdings LP acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 96,427 shares of the medical device company's stock, valued at approximately $8,321,000. DexCom makes up approximately 1.9% of HWG Holdings LP's portfolio, making the stock its 14th largest holding.

Other institutional investors have also bought and sold shares of the company. Reflection Asset Management purchased a new position in DexCom during the fourth quarter worth approximately $25,000. Ascentis Independent Advisors acquired a new stake in shares of DexCom in the 1st quarter worth $25,000. Elevation Wealth Partners LLC increased its stake in shares of DexCom by 61.0% in the 3rd quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company's stock worth $35,000 after acquiring an additional 152 shares during the last quarter. Wellington Grp LLC raised its holdings in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock worth $34,000 after acquiring an additional 475 shares during the period. Finally, Cassaday & Co Wealth Management LLC acquired a new position in shares of DexCom during the 1st quarter valued at about $44,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Royal Bank Of Canada reiterated an "outperform" rating and issued a $105.00 target price (up from $90.00) on shares of DexCom in a report on Thursday, October 1st. BTIG Research reaffirmed a "buy" rating and set a $90.00 price target (up from $80.00) on shares of DexCom in a research report on Friday, July 31st. Argus upped their price objective on DexCom from $86.00 to $96.00 and gave the company a "buy" rating in a report on Tuesday, August 4th. Robert W. Baird set a $105.00 price objective on DexCom in a research report on Friday, July 31st. Finally, Wall Street Zen raised DexCom from a "hold" rating to a "buy" rating in a research note on Sunday, September 6th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $91.96.

Insider Buying and Selling at DexCom

In related news, insider Kevin Sayer sold 26,756 shares of the stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the transaction, the insider owned 328,970 shares of the company's stock, valued at approximately $25,106,990.40. This represents a 7.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of the firm's stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $86.15, for a total value of $220,974.75. Following the transaction, the executive vice president owned 123,478 shares of the company's stock, valued at $10,637,629.70. This trade represents a 2.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 49,313 shares of company stock valued at $3,945,875. Corporate insiders own 0.28% of the company's stock.

DexCom Stock Performance

Shares of DXCM stock opened at $84.30 on Thursday. The firm's 50 day moving average price is $87.33 and its 200-day moving average price is $74.97. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59. The firm has a market cap of $31.81 billion, a P/E ratio of 33.32, a P/E/G ratio of 1.40 and a beta of 1.48.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.09. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm's revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.48 EPS. As a group, equities research analysts predict that DexCom, Inc. will post 2.64 EPS for the current year.

About DexCom

DexCom, Inc NASDAQ: DXCM develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.

The company's product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.